Loading stock data…
$6.69-0.19 (-2.71%)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Capricor Therapeutics, Inc. in the Healthcare sector is trading at $6.69 with a market capitalization of $389M. Wall Street consensus targets $27.00 (5 analysts), implying a +303.3% move over the next 12 months. The stock is currently near its 52-week low of $2.96, remaining 69.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$42.95M↓ | -$36.77M↓ | -$29.16M↓ | -$26.28M↑ | -$27.72M |
| Net Income | -$40.73M↓ | -$33.94M↓ | -$30.17M↓ | -$24.57M↑ | -$25.91M |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the Un...